What is Veritas Intercontinental?
Veritas Intercontinental operates as a specialized leader in clinical genomics, functioning as a bridge between raw genetic data and actionable medical information. Founded in 2018 to spearhead the international expansion of the Veritas brand, the company provides a comprehensive suite of genetic services, including maternal-fetal medicine and advanced exome analysis. By utilizing proprietary AI-driven platforms, the firm transforms complex biological sequences into personalized health insights, adhering to the highest standards of medical guidelines. Their market position is characterized by a dual focus on technological innovation and clinical excellence, serving both healthcare providers and individual patients seeking to optimize their long-term well-being through precision medicine.
How much funding has Veritas Intercontinental raised?
Veritas Intercontinental has raised a total of $8.8M across 2 funding rounds:
Series A
$3M
Series B
$5.8M
Series A (2009): $3M with participation from Ascent Venture Partners and Cedar fund
Series B (2020): $5.9M led by Charme Capital Partners, Graham Snudden, Stemar Capital Partners, and Amadeus Capital Partners
Key Investors in Veritas Intercontinental
Amadeus Capital Partners
A London-based global technology venture capital firm that invests in high-growth companies from seed to later stages across sectors such as artificial intelligence, digital health, and deep tech.
Charme Capital Partners
A pan-European private equity firm focused on mid-market companies, providing strategic capital to support international growth and operational transformation.
Ascent Venture Partners
A venture capital firm specializing in early-stage investments, primarily targeting innovative technology companies with the potential for significant market disruption.
What's next for Veritas Intercontinental?
Looking ahead, the infusion of capital will likely accelerate the company's R&D initiatives, particularly in the refinement of its AI-driven interpretation engines. As the global scientific community expands its understanding of the human genome, Veritas Intercontinental is poised to integrate these discoveries into its service portfolio, maintaining its competitive edge in the digital health landscape. The strategic focus will remain on operational scaling and the deepening of its clinical partnerships, ensuring that the company remains at the forefront of the personalized medicine revolution while navigating the regulatory complexities of international genetic testing markets.
See full Veritas Intercontinental company page
